Climb Bio Phase 1 Data Support CLYM116 Q12W Dosing in IgA Nephropathy
Wellesley Hills, Mass., September 3, 2026 Climb Bio announced positive initial Phase 1 clinical data for CLYM116, its investigational...
kidney disease
Advertisement
Arch Biopartners Gains U.S. IRB Approval for LSALT Phase II
TORONTO, Canada, August 31, 2026 Arch Biopartners Inc. announced that it has received central Institutional Review Board (IRB) approval...
AES Cleanroom Technology Gains FM 4882 Approval
MONTGOMERYVILLE, PENNSYLVANIA, Aug 27, 2026 AES Cleanroom Technology announced that its modular cleanroom wall and ceiling panel system has...
Fresenius Medical Care Reports Lower Mortality With HDF
BAD HOMBURG, GERMANY, Aug 27, 2026 Fresenius Medical Care has announced the publication of a large multinational real-world evidence...
Arch Biopartners Expands LSALT Peptide Phase 2 Kidney Injury Trial to U.S.
TORONTO, Canada, August 11, 2026 Arch Biopartners Inc. announced plans to expand its ongoing Phase 2 clinical trial of...
Advertisements
Eton Expands Infantile Hemangioma Franchise with ASN-001 Acquisition
DEER PARK, Ill., August 5, 2026 Eton Pharmaceuticals has licensed the U.S. rights to ASN-001 (timolol topical gel) from...
Mironid Raises $46 Million to Advance ADPKD Therapy
Glasgow, Scotland, August 5, 2026 Mironid has successfully raised $46 million in a Series B financing round to accelerate...
Otsuka Advances VOYXACT with Landmark Two-Year Phase 3 IgAN Results
TOKYO, Japan, August 4, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced new two-year...
U.S. Renal Care Expands Advanced HDx Dialysis Access
PLANO, Texas, July 30, 2026 U.S. Renal Care (USRC) is expanding the availability of medium cut-off (MCO) dialyzers to...
NIPRO Wins FDA Clearance for ELISIO-HX Expanded HD Dialyzer
OSAKA, Japan, July 30, 2026 NIPRO CORPORATION has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its...
Advertisement
